Literature DB >> 31593583

A Semiquantitative Scoring System May Allow Biopsy Diagnosis of Pulmonary Large Cell Neuroendocrine Carcinoma.

Marina K Baine1, John H Sinard2, Guoping Cai2, Robert J Homer2.   

Abstract

OBJECTIVES: The aim of this study was to devise reproducible biopsy criteria for distinguishing pulmonary large cell neuroendocrine carcinoma (LCNEC) from non-small cell lung carcinoma (NSCLC).
METHODS: Tissue microarrays of LCNEC and NSCLC were generated from resection specimens and used as biopsy surrogates. They were stained for neuroendocrine markers, Ki-67, napsin-A, and p40, and independently analyzed by standardized morphologic criteria by four pathologists. Tumors were scored based on morphology, neuroendocrine marker expression, and Ki-67 proliferative index.
RESULTS: The average total score for LCNEC was significantly higher than for NSCLC (5.65 vs 0.51, P < .0001). Utilizing a cutoff score of 4 or higher showed 100% sensitivity and 99% specificity for LCNEC diagnosis, with an excellent agreement among four pathologists (98%).
CONCLUSIONS: The proposed semiquantitative approach based on a combination of specific morphologic and immunophenotypic features may be a useful tool for biopsy diagnosis of LCNEC. © American Society for Clinical Pathology, 2019. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Biopsy diagnosis; Large cell neuroendocrine carcinoma of the lung; Scoring criteria

Year:  2020        PMID: 31593583     DOI: 10.1093/ajcp/aqz149

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  7 in total

1.  POU2F3 in SCLC: Clinicopathologic and Genomic Analysis With a Focus on Its Diagnostic Utility in Neuroendocrine-Low SCLC.

Authors:  Marina K Baine; Christopher A Febres-Aldana; Jason C Chang; Achim A Jungbluth; Shenon Sethi; Cristina R Antonescu; William D Travis; Min-Shu Hsieh; Mee Sook Roh; Robert J Homer; Marc Ladanyi; Jacklynn V Egger; W Victoria Lai; Charles M Rudin; Natasha Rekhtman
Journal:  J Thorac Oncol       Date:  2022-06-24       Impact factor: 20.121

Review 2.  Molecular Pathology of Pulmonary Large Cell Neuroendocrine Carcinoma: Novel Concepts and Treatments.

Authors:  Masayo Yoshimura; Kurumi Seki; Andrey Bychkov; Junya Fukuoka
Journal:  Front Oncol       Date:  2021-04-22       Impact factor: 6.244

Review 3.  Multiple faces of pulmonary large cell neuroendocrine carcinoma: update with a focus on practical approach to diagnosis.

Authors:  Marina K Baine; Natasha Rekhtman
Journal:  Transl Lung Cancer Res       Date:  2020-06

4.  Prognostic impact of peripheral blood neutrophil to lymphocyte ratio in advanced-stage pulmonary large cell neuroendocrine carcinoma and its association with the immune-related tumour microenvironment.

Authors:  Masayuki Shirasawa; Tatsuya Yoshida; Hidehito Horinouchi; Shigehisa Kitano; Sayaka Arakawa; Yuji Matsumoto; Yuki Shinno; Yusuke Okuma; Yasushi Goto; Shintaro Kanda; Reiko Watanabe; Noboru Yamamoto; Shun-Ichi Watanabe; Yuichiro Ohe; Noriko Motoi
Journal:  Br J Cancer       Date:  2020-11-30       Impact factor: 7.640

Review 5.  Pathology and Classification of SCLC.

Authors:  Maria Gabriela Raso; Neus Bota-Rabassedas; Ignacio I Wistuba
Journal:  Cancers (Basel)       Date:  2021-02-16       Impact factor: 6.639

Review 6.  The Ki-67 antigen in the new 2021 World Health Organization classification of lung neuroendocrine neoplasms.

Authors:  Giuseppe Pelosi; William D Travis
Journal:  Pathologica       Date:  2021-10

Review 7.  Lung neuroendocrine neoplasms: recent progress and persistent challenges.

Authors:  Natasha Rekhtman
Journal:  Mod Pathol       Date:  2021-10-18       Impact factor: 7.842

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.